Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 11-20 of 24

Page
per page
  1. INCB28060
    A8448 INCB28060
    Target: c-MET
    Summary: C-Met inhibitor,ATP-competitive and novel
      insoluble in EtOH; insoluble in H2O; ≥5.15 mg/mL
  2. NVP-BVU972
    A8489 NVP-BVU972
    Summary: C-Met inhibitor,potent and selective
      insoluble in H2O; ≥17 mg/mL
  3. Cabozantinib malate (XL184)
    B1401 Cabozantinib malate (XL184)
    Summary: MET andVEGF receptor2 inhibitor
      ≥31.8 mg/mL
  4. Golvatinib (E7050)
    B1439 Golvatinib (E7050)
    Target: VEGFR
    Summary: C-Met/VEGFR-2 inhibitor
  5. LY2801653
    A3573 LY2801653
    Target: MET
    Summary: MET inhibitor
      ≥27.65 mg/mL
  6. MK-8033
    A3624 MK-8033
    Summary: C-MET inhibitor
      Soluble in DMSO
  7. PF-04217903 methanesulfonate
    A3712 PF-04217903 methanesulfonate
    Target: c-MET
    Summary: C-Met inhibitor,selective and ATP-competitive
      Soluble in DMSO
  8. SU5416
    A3847 SU5416
    Target: VEGFR
    Summary: VEGF receptor inhibitor and AHR agonist
      insoluble in EtOH; insoluble in H2O; ≥11.9 mg/mL
  9. ZM 323881 HCl
    B2302 ZM 323881 HCl
    Summary: selective VEGFR2 inhibitor
      Soluble in DMSO
  10. BMS-794833
    B1438 BMS-794833
    Target: MET|Flk-1
    Summary: Met/VEGFR-2 inhibitor,potent and ATP-competitive
      ≥23.45 mg/mL

Items 11-20 of 24

Page
per page